Allergy Therapeutics PLC Director Resignation

RNS Number : 0502J

Allergy Therapeutics PLC

03 April 2024

 

 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Director Resignation

 

03 April 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that Mary Tavener has resigned as a Non-Executive Director of the Group with immediate effect.  

 

The Board wishes to thank Mary for her valued contribution to the Company over five years of service.

 

-  ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

[phone]

 

ICR Consilium

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

 

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAITMFTMTAMBRI